AZN — AstraZeneca PLC stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - General·UK

Latest market price

156.94

-3.10-1.94%

Overview Short InterestFilings

AZNQT39AstraZeneca PLC·NASDAQ

Overview Short InterestFilings

156.94-1.94%

News

Down 1.9% — AstraZeneca COPD data back Citi's $7b peak sales case (proactiveinvestors.co.uk).

Medium confidence

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NVS-0.16%$137.48 AMGN-0.48%$391.27 NVO-1.33%$44.56 GILD-0.68%$145.65 MRK-0.58%$147.60 PFE-0.04%$27.78 ABBV+0.86%$250.91 BMY-0.43%$64.41

Snapshot

Index	-	P/E	23.56	EPS (ttm)	6.66	Insider Own	0.00%	Shs Outstand	1.55B	Perf Week	-3.40%

Market Cap	243.26B	Forward P/E	13.68	EPS next Y	11.47	Insider Trans	-38.17%	Shs Float	1.54B	Perf Month	-3.07%

Enterprise Value	270.50B	PEG	1.86	EPS next Q	2.60	Inst Own	81.56%	Short Float	0.12%	Perf Quarter	-14.44%

Income	10.45B	P/S	3.96	EPS this Y	53.70%	Inst Trans	0.00%	Short Ratio	0.67	Perf Half Y	-19.51%

Sales	61.37B	P/B	4.84	EPS next Y	12.10%	ROA	8.96%	Short Interest	1.89M	Perf YTD	-10.58%

Book/sh	32.46	P/C	49.02	EPS next 5Y	12.66%	ROE	21.68%	52W High	212.71 -26.22%	Perf Year	-3.79%

Cash/sh	3.20	P/FCF	29.85	EPS past 3/5Y	45.80% 21.80%	ROIC	12.69%	52W Low	146.10 7.42%	Perf 3Y	15.40%

Dividend Est.	2.12 (1.35%)	EV/EBITDA	13.08	Sales past 3/5Y	9.82% 17.15%	Gross Margin	79.27%	Volatility	2.08% 1.70%	Perf 5Y	35.12%

Dividend TTM	3.23 (2.06%)	EV/Sales	4.41	EPS Y/Y TTM	48.00%	Oper. Margin	22.69%	ATR (14)	3.70	Perf 10Y	143.36%

Dividend Ex-Date	Aug 07, 2026	Quick Ratio	0.67	Sales Y/Y TTM	13.49%	Profit Margin	17.02%	RSI (14)	37.81	Recom	2.63

Dividend Gr. 3/5Y	2.86% 2.46%	Current Ratio	0.89	EPS Q/Q	20.64%	SMA20	-3.28%	Beta	0.34	Target Price	186.67

Payout	47.05%	Debt/Eq	0.60	Sales Q/Q	6.41%	SMA50	-6.50%	Rel Volume	1.21	Prev Close	160.04

Employees	96,100	LT Debt/Eq	0.54	Earnings	Oct 30	SMA200	-14.46%	Avg Volume	3.20M	Price	156.94

IPO Date	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.21% -0.33%	Net Debt/EBITDA	1.34	Volume	3,873,187	Change	-1.94%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Dec-10-25	Reiterated	HSBC	Buy	$95 → $108
Dec-03-25	Reiterated	Morgan Stanley	Overweight	$93 → $103
Jul-09-25	Reiterated	Berenberg Bank		$93 → $97
Feb-13-25	Upgrade	UBS	Neutral → Buy
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-13-24	Reiterated	BMO Capital	Outperform	$89 → $88
Sep-11-24	Reiterated	BMO Capital	Outperform	$82 → $89
Sep-11-24	Upgrade	Erste Group	Hold → Buy
May-30-24	Reiterated	Argus Research	Buy	$85
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold

Latest News· Times ET

Sep-09-26

Sep-09-2605:10AM

AstraZeneca COPD data back Citi's $7b peak sales caseproactiveinvestors.co.uk

04:56AM

Jim Cramer: Reliance Is ‘Terrific,' but He Prefers This Steel Stockbenzinga.com

03:05AM

AstraZeneca drug reduces lung disease flare-ups in late-stage trialsreuters.com

Sep-08-26

Sep-08-2612:05PM

AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcriptseekingalpha.com

09:08AM

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%247wallst.com

05:18AM

AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groupswsj.com

05:15AM

AstraZeneca's cancer drug combo hits main survival goal in late-stage trialreuters.com

03:50AM

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trialsbusinesswire.com

03:45AM

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopescnbc.com

Sep-07-26

Sep-07-2606:20AM

Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approvalproactiveinvestors.co.uk

05:45AM

AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamahzacks.com

01:47AM

Anteris Technologies appoints Brent Moen as chief financial officerproactiveinvestors.com

Sep-04-26

Sep-04-2602:10PM

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancerbusinesswire.com

Sep-03-26

Sep-03-2612:25PM

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval DecisionSeekingAlpha

Sep-02-26

Sep-02-2607:11AM

AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbackszacks.com

Company

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Ownership

Total institutional ownership81.56%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	61,366	58,739	54,073	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	11,120	10,633	10,207	—	—	—	—	—	—
Gross Profit	50,246	48,106	43,866	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	21,735	20,512	20,224	—	—	—	—	—	—
Research and Development	15,070	14,232	13,583	—	—	—	—	—	—
Other Operating Expense	-530	-381	56	—	—	—	—	—	—
Operating Income	13,971	13,743	10,003	—	—	—	—	—	—
Interest Expense	1,734	1,694	1,682	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	349	353	370	—	—	—	—	—	—
Net Income Before Taxes	12,586	12,402	8,691	—	—	—	—	—	—
Income Taxes	2,133	2,169	1,650	—	—	—	—	—	—
Consolidated Net Income	10,446	10,255	7,035	—	—	—	—	—	—
Net Income From Continuing Operations	10,453	10,233	7,041	—	—	—	—	—	—
Net Income	10,446	10,255	7,035	—	—	—	—	—	—
EPS (Recurring)	6.72	6.60	4.54	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	6.72	6.60	4.54	—	—	—	—	—	—
EPS (Diluted)	6.66	6.54	4.50	—	—	—	—	—	—
EBITDA	20,675	19,829	15,438	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	23.56	26.83	28.89	—	—	—	—	—	—
Price To Sales Ratio	3.97	4.63	3.73	—	—	—	—	—	—
Gross Margin	81.88	81.90	81.12	—	—	—	—	—	—
Operating Margin	22.77	23.40	18.50	—	—	—	—	—	—
Net Margin	17.02	17.46	13.01	—	—	—	—	—	—
Shares Outstanding	1,551	1,550	1,550	—	—	—	—	—	—
Market Capitalization	243,414	272,025	201,500	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sharma Mani	See Remarks	May 20 '26	Sale	185.78	11,893	2,209,482	19,262	May 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.